Purpose. The aim of this study was to characterize treatment patterns and oncologic outcomes in patients with lowvolume lymph node metastasis (isolated tumor cells [ITCs] and micrometastasis [MM]) discovered during sentinel lymph node (SLN) mapping for endometrial carcinoma. Methods. We identified endometrial cancer cases treated surgically from September 2005 to April 2013 in which SLN mapping was performed. MM was defined as tumor within a lymph node measuring [0.2 mm but \2.0 mm, and ITCs were those measuring B0.2 mm. Results. Overall, 844 patients, with a median age of 61 years (range 30-90), met the inclusion criteria. Histology was as follows: endometrioid, 724 (85.8 %) patients; serous, 104 (12.3 %) patients; and clear cell, 16 (1.9 %) patients. The median number of lymph nodes resected was six (range 0-60), and the median number of SLNs was two (range 0-15). Overall, 753 (89.2 %) patients were nodenegative, 23 (2.7 %) had ITCs only, 21 (2.5 %) had MM only, and 47 (5.6 %) had macrometastasis. 1 The presence or absence of lymph node metastasis is a prognostic factor, as are surgical stage, grade, histology, lymphovascular space invasion, depth of myometrial invasion, cervical involvement, and extrauterine spread. As depth of invasion and tumor grade increase, so does the risk for nodal involvement.
Conclusions. Patients with ITCs and MM frequently received adjuvant chemotherapy and had improved oncologic outcomes in comparison to those with macrometastasis to the lymph nodes. Further prospective study is needed to determine optimal post-resection management in patients with ITCs or MM alone.
Endometrial cancer remains the most common gynecologic cancer diagnosed in the US, with an estimated 54,870 new cases in 2015. 1 The presence or absence of lymph node metastasis is a prognostic factor, as are surgical stage, grade, histology, lymphovascular space invasion, depth of myometrial invasion, cervical involvement, and extrauterine spread. As depth of invasion and tumor grade increase, so does the risk for nodal involvement. 2 Despite this knowledge, significant controversy surrounds the staging of endometrial carcinoma and, specifically, the performance and extent of the lymph node dissection. Practice ranges from omission of the nodal dissection to utilization of preoperative imaging or frozen section as a means of triage, to lymphadenectomy to the renal vessels for all patients. [3] [4] [5] [6] [7] Two randomized controlled trials failed to demonstrate an improvement in oncologic outcomes with comprehensive lymphadenectomy. 8, 9 However, a recent classification and regression tree (CART) analysis by Barlin et al. concluded that stage assignment significantly impacted overall survival (OS), thus stressing the importance of surgical staging and lymph node assessment.
Over the last decade, use of a sentinel lymph node (SLN) mapping algorithm for endometrial cancer has emerged as a middle ground in which all patients with endometrial cancer undergo lymph node evaluation, while limiting the morbidity associated with a full lymphadenectomy. 11 Sentinel node biopsy has been studied extensively in breast cancer and in melanoma. Within the breast literature, multiple randomized controlled trials have demonstrated an improved side effect profile and better quality-of-life outcomes for those patients who undergo SLN biopsy compared with those who undergo a full axillary lymph node dissection, without compromising regional disease control and survival endpoints. [12] [13] [14] Lymph node metastasis remained an independent (and negative) prognostic factor in breast disease, 15 but the prognostic significance of low-volume lymph node metastases remains an area of active investigation.
Ultrastaging of sentinel axillary nodes in breast cancer led to the detection of small tumor deposits within the nodes. The American Joint Committee on Cancer (AJCC) defined micrometastasis (MM) as tumor within a lymph node measuring [0.2 mm but \2.0 mm, and isolated tumor cells (ITCs) as tumor B0.2 mm. 16 One prospective study of more than 3000 patients in Sweden demonstrated a decreased 5-year disease-specific survival (DSS) in patients with MM compared with those with negative lymph nodes. 17 No significant difference in survival was observed between those with ITCs and those with negative lymph nodes; however, those with ITCs were more likely to undergo a completion axillary lymph node dissection than those without ITCs.
Use of an SLN algorithm with pathologic ultrastaging for endometrial carcinoma has led to increased detection of low-volume lymph node metastasis in the form of ITCs and MMs. 18, 19 However, the clinical significance of these findings in endometrial cancer is yet unknown. We sought to characterize treatment patterns and oncologic outcomes in those patients with endometrial cancer found to have low-volume lymph node metastasis compared with those patients with negative nodes and patients with macrometastatic nodes. We hypothesized that there would be no statistically significant difference in recurrence-free survival (RFS) between those with low-volume lymph node disease (ITCs and MM) compared with those with macrometastatic nodal involvement.
MATERIALS AND METHODS
Approval was obtained from the Institutional Review Board at Memorial Sloan Kettering Cancer Center. We identified all cases of endometrial cancer treated surgically at our institution from September 2005 through April 2013 in which the Memorial Sloan Kettering (MSK) SLN mapping algorithm was used. 11 At the time of surgery, blue dye or indocyanine green (ICG) was injected into the cervical stroma at the 3 o'clock and 9 o'clock positions to both deep and superficial levels totalling 4 mL; SLNs were excised and labeled as such, and then processed by the institution's Pathology Department per protocol. 11, 19 Lymph node status was defined as follows: lymph nodes without tumor present on pathologic evaluation were reported as negative; ITCs were defined as those measuring B0.2 mm; and MM was defined as tumor within a lymph node measuring[0.2 mm but\2.0 mm. Notably, when the tumor measurement was not delineated in the pathology report and the terms 'isolated tumor cells' and 'micrometastasis' were not used, a determination was made based on the pathology report, with clarification from a gynecologic pathologist when needed. For example, 'rare scattered tumor cells' were classified as ITCs, whereas 'diffuse clusters of cells' were defined as MM. This occurred in three cases classified as ITCs, in which the wording 'scattered' or 'single' cells was used, and in ten cases classified as MMs, in which 'clusters' of tumor were described within the node. Lymph nodes with a tumor burden C2.0 mm were reported as metastatic lymph nodes without further delineation of number or cells or the size of the metastasis.
Medical records were reviewed, including but not limited to outpatient and inpatient notes, laboratory results and imaging if pertinent, operative reports, pathology reports, and records detailing postoperative treatment, including chemotherapy and radiation therapy. All grades and histologic subtypes were included in the analysis. The stage at diagnosis was assigned based on the 1988 International Federation of Gynecology and Obstetrics (FIGO) staging for endometrial carcinoma, as the study period spanned the transition to the updated 2009 FIGO staging system. Those with intraperitoneal spread delineating stage IV disease were excluded; all other stages were included in the analysis. The primary outcome was RFS.
Clinicopathologic data were reported using median values (range) for continuous variables, and number of patients (n) and percentage (%) for categorical variables. RFS was calculated using the Kaplan-Meier method, and all statistical analyses were performed using IBM SPSS Statistics 22.0 (IBM Corporation, Armonk, NY, USA).
RESULTS
Over the study period, 844 patients who met the inclusion criteria were analyzed ( The median number of total lymph nodes collected was six (range 0-60); the median number of pelvic lymph nodes was six (range 0-53); and the median number of paraaortic lymph nodes was one (range 0-22). Fifty-one (6 %) of 844 patients had no lymph nodes removed; these patients predominantly fell into two categories. In the first group, patients were injected for SLN mapping but failed to map; therefore, frozen section was obtained and the surgeon used intraoperative uterine criteria to defer lymph node dissection. The second group consisted of patients in whom tissue was sent as nodal tissue but no lymph nodes were identified on final pathology. The median number of SLNs was two (range 0-15). Only one patient had 15 SLNs removed, and this was a case of serous endometrial cancer; it is unclear based on review of the chart whether 15 lymph nodes were mapped or whether additional nodes were taken given the serous histology. Patients with any evidence of nodal metastasis, whether ITCs, MMs or macrometastases, were considered stage IIIC and were evaluated for adjuvant therapy. The type of adjuvant therapy administered to those patients with lowvolume lymph node metastasis varied (Table 2 ). In the cohort of 23 patients with ITCs, 20 (87.0 %) received chemotherapy postoperatively. Of these, 19 received chemotherapy in combination with radiation therapy; 12 (52.2 %) received chemotherapy with intravaginal radiation therapy (IVRT), and 7 (30.5 %) received combined chemotherapy and intensity-modulated radiation therapy (IMRT). In the group with MMs, 17 of 21 (81.0 %) patients received chemotherapy in the adjuvant setting. Ten (47.6 %) patients received chemotherapy plus IMRT, while recurred; of those with MM, 2 of 21 (9.5 %) recurred; and, of the 46 patients with nodal macrometastases, 16 (34.8 %) recurred. The distribution of recurrences is shown in Table 3 . Figure 2a represents the Kaplan-Meier curve for RFS by nodal status. With a median follow-up of 26 months (range 0-108), the 3-year RFS for those with negative lymph nodes was 90 % (±1.5). The 3-year RFS was 86 % (±9.4) for those with ITCs, 86 % (±9.5) or those with MM, and 71 % (±7.2) for those with nodal macrometastases [p \ 0.001]. Given that the total cohort of 844 patients was composed of all histologies, we then looked at the RFS for the 724 patients with endometrioid endometrial cancer (Fig. 2b) . These are the patients most likely to undergo SLN mapping with ultrastaging and the patients whose adjuvant treatment may depend heavily on lymph node status. Here, the 3-year RFS was 93 % (±1.4) for those with negative lymph nodes, 94 % (±6.1) for those with ITCs, 92 % (±7.4) for those with MM, and 85 % (±6.9) for those with nodal macrometastases (p \ 0.001). There were only four ITC and four MM cases within the non-endometrioid histology cohort. Meaningful survival outcome analysis was not possible in this specific cohort.
DISCUSSION
In our study population of more than 800 patients with endometrial carcinoma treated surgically in which an SLN algorithm was used, the vast majority of patients found to have low-volume metastases received postoperative treatment including chemotherapy. When treated with surgery and adjuvant therapy, the oncologic outcomes for patients in our cohort with ITCs and MM were improved over those with macrometastasis, with a statistically significant improvement in 3-year RFS. ITCs isolated tumor cells, MM micrometastasis, IVRT intravaginal radiation therapy, IMRT intensity-modulated radiation therapy, WPRT whole-pelvic radiation therapy
The literature regarding technique, feasibility, and detection rates for SLNs in endometrial cancer continues to grow. 20, 21 However, data regarding clinical outcomes in the setting of low-volume lymph node metastasis in endometrial cancer are lacking. The study by Todo et al. looked at 63 patients with FIGO stage I-II endometrial carcinoma with at least one adverse risk factor: grade 3 tumor, serous/clear cell histology, deep myoinvasion, cervical involvement, LVSI, or positive peritoneal washings. 22 Within the cohort, ITCs and MM were identified in nine (14.8 %) patients. They found that the presence of ITC/ MM was an independent risk factor for recurrence (hazard ratio 17.9; 95 % CI 1.4-232.2). The 8-year OS and RFS rates were lower in the ITC/MM group than in the nodenegative group (OS 71.4 % vs. 91.9 %; RFS 55.6 % vs. 84.0 %); however, given the small number of patients, statistical significance was not reached. Furthermore, with only nine patients with low-volume metastases, the authors did not distinguish between those with ITCs versus MM.
With a total of more than 800 patients and 44 with lowvolume metastasis, our sample size is a strength of the study. Additionally, our study benefits from the participation of dedicated gynecologic pathologists with over 10 years' experience evaluating SLNs in gynecologic cancers. However, we acknowledge the limitations of our data. Patients with ITCs and MM were treated as nodepositive. As such, the great majority of patients received adjuvant therapy, and in this study we are unable to comment on the natural history of patients with untreated lowvolume metastasis. There is concern by some that we may be overtreating patients with ITCs and MM, and that they would do well without adjuvant therapy. While overtreatment should be avoided, it is important to note that only 5 % of our study population of 844 patients was found to have low-volume lymph node metastasis, in whom adjuvant therapy may have been omitted had these positive lymph nodes gone undetected. Prospective study will be necessary to further inform the discussion regarding optimal post-resection management in this patient population.
Finally, the therapeutic benefit of lymphadenectomy to remove metastatic disease in non-SLNs remains unknown. In this cohort, patients with low-volume lymph node disease were treated postoperatively; however, none were brought back to the operating room for completion lymph node dissection. Our study does not address the question of 'debulking' of grossly normal-appearing, but potentially metastatic, lymph nodes. Data recently published by Touhami et al. looked at those factors that predict the presence of non-SLN metastasis when the SLN is positive. 23 They evaluated 268 patients who underwent surgical staging for endometrial cancer including SLN mapping and pelvic lymphadenectomy, and found that the size of the metastasis 
CONCLUSIONS
Our findings point to improved RFS in endometrial cancer patients with low-volume lymph node metastases treated in the adjuvant setting in comparison to those with macrometastatic disease to the lymph nodes. Prospective study is needed to determine optimal postoperative treatment for patients with ITCs and MM alone. Until that time, our institution will continue to treat these patients as nodepositive, recommending adjuvant therapy and fully recognizing that this may possibly be overtreatment in some patients. The MSK treatment algorithm for patients with stage IIIC disease calls for cisplatin 50 mg/m 2 on days 1 and 29 plus volume-directed radiation therapy, followed by paclitaxel and carboplatin for four cycles. Alternatively, patients may be treated with chemotherapy (paclitaxel and carboplatin for six total cycles) with or without vaginal brachytherapy. The decision to proceed with one or the other depends on additional clinicopathologic features as well as patient and provider preference. GOG 258 compares these two regimens and will hopefully provide information to help support one regimen over the other. We will continue to closely follow those patients who have declined treatment in order to obtain additional data regarding the natural history of ITCs and MM in endometrial carcinoma.
